CCR5 antagonists: host-targeted antivirals for the treatment of HIV infectionWESTBY, Mike; VAN DER RYST, Elna.Antiviral chemistry & chemotherapy. 2005, Vol 16, Num 6, pp 339-354, issn 0956-3202, 16 p.Article

Inhibitors of Viral EntryMELBY, Tom; WESTBY, Mike.Handbook of experimental pharmacology. 2009, Vol 189, pp 177-202, issn 0171-2004, 26 p.Article

HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage TropismROCHE, Michael; JAKOBSEN, Martin R; CHURCHILL, Melissa J et al.Journal of virology. 2011, Vol 85, Num 9, pp 4330-4342, issn 0022-538X, 13 p.Article

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entryWESTBY, Mike; SMITH-BURCHNELL, Caroline; MORI, Julie et al.Journal of virology. 2007, Vol 81, Num 5, pp 2359-2371, issn 0022-538X, 13 p.Article

A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maravirocROSARIO, Maria C; POLAND, Bill; SULLIVAN, John et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 42, Num 2, pp 183-191, issn 1525-4135, 9 p.Article

Knockdown of USP18 Increases Alpha 2a Interferon Signaling and Induction of Interferon-Stimulating Genes but Does Not Increase Antiviral Activity in Huh7 CellsMURRAY, E. J; BURDEN, Frances; HORSCROFT, Nigel et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 9, pp 4311-4319, issn 0066-4804, 9 p.Article

Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitorsWESTBY, Mike; NAKAYAMA, Grace R; BUTLER, Scott L et al.Antiviral research. 2005, Vol 67, Num 3, pp 121-140, issn 0166-3542, 20 p.Article

Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antiviralsGRAHAM, Emily J. S; HUNT, Rachael; SHAW, Stephen M et al.Journal of virological methods. 2011, Vol 174, Num 1-2, pp 153-157, issn 0166-0934, 5 p.Article

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 InfectionCOOPER, David A; HEERA, Jayvant; REEVES, Jacqueline D et al.The Journal of infectious diseases. 2010, Vol 201, Num 6, pp 803-813, issn 0022-1899, 11 p.Article

Baseline CD4⁺ T―cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment―experienced patientsSCHAPIRO, Jonathan M; BOUCHER, Charles Ab; PERROS, Manos et al.Antiviral therapy (London). 2011, Vol 16, Num 3, pp 395-404, issn 1359-6535, 10 p.Article

A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1SAAG, Michael; GOODRICH, James; FÄTKENHEUER, Gerd et al.The Journal of infectious diseases. 2009, Vol 199, Num 11, pp 1638-1647, issn 0022-1899, 10 p.Article

Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic OverlaysJONES, Lyn H; ALLAN, Gill; PERROS, Manos et al.Journal of medicinal chemistry (Print). 2009, Vol 52, Num 4, pp 1219-1223, issn 0022-2623, 5 p.Article

Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoirWESTBY, Mike; LEWIS, Marilyn; WHITCOMB, Jeannette et al.Journal of virology. 2006, Vol 80, Num 10, pp 4909-4920, issn 0022-538X, 12 p.Article

Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase MultimerizationCHRIST, Frauke; SHAW, Stephen; PICKFORD, Chris et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 8, pp 4365-4374, issn 0066-4804, 10 p.Article

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1CORBAU, Romuald; MORI, Julie; KNÖCHEL, Thorsten et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 10, pp 4451-4463, issn 0066-4804, 13 p.Article

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 InfectionFÄTKENHEUER, Gerd; NELSON, Mark; BELLOS, Nicholaos et al.The New England journal of medicine. 2008, Vol 359, Num 14, pp 1442-1455, issn 0028-4793, 14 p.Article

Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected PatientsTROKE, Philip J. F; LEWIS, Marilyn; SIMPSON, Paul et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 3, pp 1331-1341, issn 0066-4804, 11 p.Article

Small Molecules Targeting Hepatitis C Virus-Encoded NS5A Cause Subcellular Redistribution of Their Target: Insights into Compound Modes of ActionTARGETT-ADAMS, Paul; GRAHAM, Emily J. S; STAMMEN, Blanda et al.Journal of virology. 2011, Vol 85, Num 13, pp 6353-6368, issn 0022-538X, 16 p.Article

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activityDORR, Patrick; WESTBY, Mike; WEBSTER, Rob et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 11, pp 4721-4732, issn 0066-4804, 12 p.Article

Loss of CD4⁺ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to diseaseWILSON, Jamie D. K; IMAMI, Nesrina; WATKINS, Amanda et al.The Journal of infectious diseases. 2000, Vol 182, Num 3, pp 792-798, issn 0022-1899Article